i
RSV Vaccination in Older Adults: Benefit-Risk Discussion
-
February 29, 2024
[PDF-782.46 KB]
Details:
-
Personal Author:
-
Corporate Authors:
-
Conference Authors:
-
Subjects:
-
Document Type:
-
Name as Subject:
-
Genre:
-
Collection(s):
-
Main Document Checksum:urn:sha256:b470daa4c9c47d6f15ad730886d75b1f122e2fbafc470c55af7b6c7af38f0469
-
File Type:
Supporting Files
-
No Additional Files
More +
Related Documents
-
Personal Author:Self, Wesley H. ;Rouphael, Nadine...February 29, 2024 | ACIP meeting Pneumococcal VaccinesDescription:Funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USAhttps://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2024-...Personal Author:Das, RituparnaFebruary 29, 2024 | ACIP meeting Respiratory Syncytial Virus (RSV) Older Adults VaccineDescription:The safety and efficacy of this investigational RSV vaccine have not been established in any country for any use02-RSV-Adults-Das-508.pdf
More +
You May Also Like
Checkout today's featured content at stacks.cdc.gov